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Abstract 
The time at which the N-ethylmaleimide-sensitive factor (NSF) acts during 
synaptic vesicle trafficking was identified by time-controlled perturbation of NSF 
function with a photo-activatable inhibitory peptide. Photolysis of this caged 
peptide in the squid giant presynaptic terminal caused an abrupt (0.2 s) slowing 
of the kinetics of the postsynaptic current (PSC) and a more gradual (2-3 s) 
reduction in PSC amplitude. Based on the rapid rate of these inhibitory effects 
relative to the speed of synaptic vesicle recycling, we conclude that NSF 
functions in reactions that immediately precede neurotransmitter release. Our 
results indicate the locus of SNARE protein recycling in presynaptic terminals 
and reveal a new target for rapid regulation of transmitter release. 
 
 
 3 
Introduction 
 
Neurotransmitter release relies on the precisely coordinated actions of many 
proteins that serve to recruit synaptic vesicles (SV) to active zones, prepare SVs 
for Ca2+-dependent exocytosis, and recycle used components (1-5). At the core 
of these trafficking reactions lies the SNARE (soluble NSF attachment protein 
receptor) complex, which consists of proteins present in synaptic vesicles 
(v-SNAREs) and the plasma membrane (t-SNAREs) (6). It is thought that 
trans-SNARE complexes bridging the SV and plasma membranes bring these 
two membranes into close apposition and mediate membrane fusion (7, 8). 
Because SNARE complexes are highly stable, hydrolysis of ATP by the molecular 
chaperone NSF (9, 10) is required to disassemble used SNARE complexes and, 
thereby, recycle SNARE proteins in preparation for future rounds of exocytosis 
(11-13). Although it is generally agreed that this action of NSF is important for 
neurotransmitter release, it is not clear whether NSF works before or after 
vesicle fusion. This distinction is critical for understanding the dynamic control of 
synaptic transmission by NSF and for elucidating the life cycle of SNARE 
complexes during SV trafficking.  
 
Two models have been proposed for the timing of NSF action during 
neurotransmitter release (Fig. 1). SNAREs could be disassembled just before 
fusion, meaning that NSF is active only when needed for a fusion reaction (Fig. 
1A). This is consistent with observations that NSF is required prior to vesicle 
fusion in several experimental systems (14-20). Alternatively, NSF could 
dissociate SNARE complexes immediately after neurotransmitter release (Fig. 
1B). Such a post-fusion action of NSF could provide an attractive mechanism for 
sorting of v- and t-SNAREs following fusion: in this case, newly separated 
v-SNAREs would be carried along as recycled SVs bud from the plasma 
membrane, while t-SNAREs would remain behind in the plasma membrane. 
Although experimental evidence supporting this conclusion is limited (21, 22), 
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the ability to explain SNARE sorting makes a post-fusion action of NSF part of 
most current models of SV trafficking (8, 23-26). 
 
One way to distinguish between these two alternatives is to inactivate the 
function of NSF acutely in living presynaptic nerve terminals. A post-fusion block 
of NSF would slowly inhibit transmitter release, over the 45-90 seconds required 
for SV cycling (27), while a pre-fusion block would more rapidly inhibit release 
(Fig. 1C). We therefore designed and synthesized a light-sensitive (caged) 
inhibitor of NSF. Our strategy was based on incorporating a caging group onto a 
key amino acid of a peptide that blocks the αSNAP-stimulated ATPase activity of 
NSF in vitro (28-30). This peptide prevents the NSF-mediated disassembly of 
the SNARE complex (28) and inhibits neurotransmitter release when injected 
into presynaptic terminals (30, 31).  
 
By using this caged peptide to perturb NSF function, we found that the amount 
of neurotransmitter release was inhibited with a latency ranging from 1.6 to 3.2 
s. Furthermore, the kinetics of neurotransmitter release was decreased even 
more rapidly, with a latency of 0.2 s. These very rapid actions of the uncaged 
inhibitory peptide lead us to conclude that the physiologically relevant locus of 
NSF action in the synaptic vesicle cycle is immediately upstream of membrane 
fusion and release of neurotransmitter. 
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Results 
 
Design of caged NSF3 peptide  
Our caged NSF inhibitor was based on the NSF3 peptide (30) derived from the 
D1 domain of squid NSF (Fig. 2A,B). Structural data suggests that the amino 
acid residues constituting this peptide are located at the external surface of the 
D1 domain, in close proximity to the N domain (Fig. 2B, blue). A glycine residue 
within this segment of NSF (Fig. 2A, underlined) is critical for the actions of both 
NSF (32, 33) and the NSF3 peptide (30). We sought to disrupt the active 
conformation of the peptide by placing a caging group onto the side chain of an 
amino acid near this glycine. For this purpose, we used a 
((5-carboxy-methoxy-2-nitrobenzyl)oxy)carbonyl (CMNCBZ) cage (Fig. 2C) that 
was attached to a surface-exposed lysine residue (Fig. 2A, red) two residues 
upstream of the critical glycine residue. Following UV illumination, photolysis of 
this cage proceeds in two steps (Fig. 2C). The first step takes less than 1 ms and 
causes most of the cage to dissociate from the peptide; the second step, a 
spontaneous decarboxylation, is half-complete within 4.5 ms (34). The 
photolyzed peptide may assume its active conformation after the first step, but 
after the subsequent decarboxylation step it should be identical to the 
non-caged NSF3 peptide. Therefore the peptide should be in an active 
conformation within a few ms or less after UV illumination. 
 
Photolysis of caged peptide inhibits neurotransmitter release 
To define when NSF is required in the SV cycle, the caged NSF3 peptide (cNSF3) 
was microinjected into the presynaptic terminal of the squid giant synapse at 
concentrations of 0.05-2.5 mM, while monitoring synaptic transmission via 
recordings of presynaptic and postsynaptic (PSPs) potentials. The CMNCBZ cage 
masked the inhibitory activity of the peptide, because in each of 66 experiments 
uncaging the peptide with a brief pulse of UV light inhibited synaptic 
transmission (Fig. 3A). The time course of this block was rapid, occurring within 
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a few seconds or less (Fig. 3B). Synaptic transmission decreased during cNSF3 
injection, indicating that the cage did not completely neutralize peptide activity 
(Fig. 3C). However, the CMNCBZ cage caused a four-fold increase in the IC50 of 
caged NSF3 (0.35 ± 0.08 mM) compared to non-caged peptide (0.08 ± 0.01 
mM), which gave us sufficient dynamic range to control NSF function.  
 
Previous work has established the specificity of non-caged NSF3 peptide. Key 
arguments are that: (i) both NSF3 and another peptide from the external 
surface of the D1 domain have identical inhibitory effects both on ATPase 
activity and on synaptic transmission; and (ii) mutation of the glycine residue, 
which inhibits NSF function in vivo (32, 33), completely abolishes the ability of 
NSF3 to inhibit both ATPase activity and synaptic transmission (30). Mass 
spectroscopy reveals that exposure to UV light produces a peptide that is 
identical to non-caged NSF3 (unpublished data), so that the biochemical 
properties of NSF3 defined in previous work (30, 31) should fully apply to 
uncaged cNSF3. Nonetheless, to consider possible side-effects of uncaging 
cNSF3, we performed two control experiments. First, we uncaged a scrambled 
NSF3 peptide. This peptide had the same amino acid composition as cNSF3, 
including the presence of a CMNCBZ-caged lysine residue, but does not 
resemble NSF3. In a total of 11 experiments, photolysis of this control peptide 
produced no effect on synaptic transmission, even when illuminating the 
terminal with up to 750 mJ/mm2 and at free cage concentrations as high as 0.9 
mM (Fig. 3D). Photolysis of a second control compound, CMNCBZ-caged 
rhodamine, was similarly ineffective (n = 5; data not shown). These results 
indicate that inhibition of neurotransmitter release was caused directly by the 
liberated NSF3 peptide, rather than being caused by UV illumination or by 
production of free CMNCBZ cage or CO2. Thus, caging a single lysine residue 
decreased the biological activity of the NSF3 peptide about 4-fold, allowing flash 
photolysis to very rapidly control the molecular machinery of neurotransmitter 
release. 
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The NSF3 peptide both decreases synaptic transmission and slows the kinetics 
of neurotransmitter release (30). To determine the relationship between these 
two actions, we examined how quickly each developed following cNSF3 
photolysis. For this purpose, postsynaptic currents (PSCs) were recorded while 
photolyzing cNSF3. Figure 4A shows a series of simultaneous pre- and 
postsynaptic recordings during photolysis of cNSF3. PSCs were elicited every 
second, with the pre-flash PSC shown as a black trace. Following a pulse of UV 
light, which was applied at the same time as a presynaptic action potential, the 
next PSC was virtually unchanged in amplitude yet clearly had slower kinetics 
(Fig. 4A, largest red trace). Both PSC rise time and decay were slowed following 
peptide uncaging, as readily observed when comparing PSCs scaled to the same 
peak amplitude (Fig. 4B). While this change in PSC kinetics was virtually 
immediate, occurring in less than 1 second, the inhibition of PSC amplitude 
required several seconds for completion (Fig. 4C). Similar results were obtained 
in a total of 14 experiments. Hence, temporally precise activation of the caged 
peptide revealed distinct time courses for the two actions of NSF3: a fast effect 
on the kinetics of neurotransmitter release and a slower effect on the amount of 
neurotransmitter released.  
 
Time course of the two responses to uncaged NSF3 
We quantified the time course of the slow effect of NSF3 by fitting exponential 
functions to data such as those shown at the top of Fig. 4C. The time constant 
for inhibiting PSC amplitude was activity-dependent and ranged from 3.1 s at 
0.2 Hz to 1.6 s at 5 Hz (Fig. 5A). This acceleration of the rate of inhibition at 
higher rates of stimulation is consistent with previous observations of the 
activity-dependence of this peptide (30) and full-length NSF (32, 33). Uncaged 
NSF3 also had some effect in the absence of activity: when stimulating at 0.2 Hz, 
the first PSC evoked 5 seconds after photolysis of the peptide was reduced by 
75% (Fig. 5A). This may reflect a continuous activity of NSF (20) in the resting 
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presynaptic terminal. Thus, NSF regulates the amount of neurotransmitter 
release over a time scale of a few seconds or less.  
 
Given the rapid effect of uncaged NSF3 upon release kinetics, a different 
procedure was needed to determine the time course of this effect. For this 
purpose, we uncaged cNSF3 at different intervals preceding an action potential 
(Fig. 5B, inset). At very brief time intervals, the amount of slowing of PSC 
kinetics was minimal, but the slowing effect was complete if the light flash 
occurred 1 s before the synapse was activated. The relationship between 
pre-flash interval (Δt) and degree of slowing of the PSC decay was described by 
an exponential function with a time constant of 0.22 s (Fig. 5B). This time 
constant represents an upper estimate of the time period when NSF3 affects 
release kinetics, because of possible delays associated with photolysis of the 
CMNCBZ cage and with binding of uncaged NSF3 peptide to its target. Therefore, 
NSF regulates the kinetics of release over a time scale of 0.22 s or faster.  
 
Because the time scales of the inhibitory effects of uncaged NSF3 peptide are 
very rapid relative to the tens of seconds or longer required for vesicles to 
recycle via conventional (45 - 90 s (27)) or kiss-and-run (t ~ 20 s (35, 36)) 
mechanisms of endocytosis, our data argue that NSF is required before 
neurotransmitter release occurs rather than acting after membrane fusion (Fig. 
1). However, the high rate of synaptic activity in the experiments shown in Figs. 
5A and 5B may cause a redistribution of SNARE complexes to the plasma 
membrane; if NSF was required to dissociate these cis-SNARE complexes after 
fusion, then inhibiting such a post-fusion action of NSF might prevent 
transmitter release by accumulating SNARE complexes in the plasma membrane. 
To examine this possibility, the experiments were repeated at a minimal rate of 
synaptic activity (0.03 Hz). The rate of onset of the kinetic effect was very 
similar at this low rate of stimulation, with a time constant of approximately 0.5 
s (Fig. 5C). This reveals that uncaged NSF3 peptide rapidly slows the kinetics of 
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release even under conditions where plasma membrane accumulation of SNARE 
complexes should be minimal, reinforcing the conclusion that NSF works before 
membrane fusion. 
 
The temporally distinct effects of uncaged NSF3 on release magnitude and 
kinetics suggest that the peptide causes these two effects via separate 
mechanisms. Further support for this comes from analysis of the 
concentration-dependence of these two effects (Fig. 5D). The fast effect 
occurred at higher concentrations of NSF3 (IC50 of 0.28 ± 0.02 mM) than the 
slow effect (IC50 of 0.06 ± 0.01 mM). Thus, binding of NSF3 at two different 
sites may affect two separate NSF-dependent reactions: a higher affinity one 
that slowly affects the magnitude of transmitter release and a lower affinity one 
that rapidly affects the kinetics of release. Alternatively, NSF3 may bind at only 
one site, with the difference in affinity and functional effects reflecting different 
conformational states of the binding site (e.g. ATP- versus ADP-bound states of 
NSF (12, 37)). 
 
NSF3 does not prevent membrane fission 
To further address a possible post-fusion role for NSF, we asked whether 
photolysis of cNSF3 directly affects endocytic membrane retrieval. By taking 
advantage of the slower kinetics of endocytosis relative to exocytosis, we could 
temporally uncouple endocytosis from exocytosis by selectively uncaging cNSF3 
after exocytosis was completed. Presynaptic membrane capacitance was 
directly measured at the nerve terminal in the unperturbed state (Fig. 6, upper 
panel) and immediately following cNSF3 photolysis (Fig. 6, red). After an initial 
increase in capacitance, due to exocytosis triggered by high-frequency 
stimulation (grey area), the capacitance decreased gradually to baseline. The 
decays could be described with exponential functions with time constants of 149 
± 29 s before and 131 ± 22 s after photolysis of cNSF. These values were not 
significantly different (N=5, p=0.15, t-test), indicating that the speed of 
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endocytosis is not affected by inhibiting NSF function. Thus, if NSF has any 
post-fusion role, this role does not affect the rate of membrane fission during 
endocytosis and is not rate-limiting for exocytosis. 
 
 
 
Discussion 
 
We have used a caged inhibitor peptide to provide novel information about the 
timing of NSF action in synaptic vesicle trafficking. Our studies provide much 
higher time resolution (milliseconds) than was possible in previous work, 
including studies of a Drosophila temperature-sensitive NSF mutation (22,33). 
Because of this high time resolution, we could determine for the first time that 
NSF participates in two rapid reactions with time constants of a few seconds or 
less. Both the fast (0.22 s) and slow (2-3 s) effects of the NSF3 peptide occur on 
a time scale much faster than synaptic vesicle endocytosis and recycling (27, 35, 
36), we conclude that these effects represent pre-fusion actions of NSF  (Fig. 7). 
Formally speaking, NSF could still have additional actions after vesicle fusion 
(22). While our capacitance measurements indicate that NSF action is not 
required for endocytic membrane retrieval, other post-fusion actions could be 
masked by the rapid onset of photolyzed peptide and therefore remain 
undetected. Nevertheless, our results indicate that a pre-fusion action of NSF 
must be responsible for the ability of this chaperone to regulate the magnitude 
and kinetics of transmitter release. This extends previous work, largely done in 
non-neuronal cells, suggesting that NSF participates in vesicle priming and 
resolves a long-standing question about when NSF functions in synaptic vesicle 
trafficking.  
 
The slower, activity-dependent reaction occurring on a time scale of several 
seconds likely reflects the disassembly of cis-SNARE complexes upon docking of 
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SV at the active zone (steps 1-3 in Fig. 7). Inhibition of the αSNAP-stimulated 
ATPase activity of NSF by uncaged NSF3 peptide (30) would prevent 
NSF-dependent disassembly of cis-SNARE complexes (28) and thereby reduce 
the amount of uncomplexed SNARE proteins available after SVs are docked at 
the active zone. This would reduce the amount of neurotransmitter release, 
which requires formation of trans-SNARE complexes (3-5), and could account 
for the increase in docked SVs in terminals injected with NSF3 (30) as well as 
the accumulation of transport vesicles at acceptor membranes in the absence of 
NSF (38, 39). Thus, NSF appears to prime tethered SVs for release, as 
previously concluded for non-neuronal forms of membrane fusion and also 
suggested for neurotransmitter release (14-20). This can account for the 
activity-dependence of NSF3 action: synaptic transmission would not be 
inhibited immediately after uncaging cNSF3, because of the presence of primed 
SVs at the active zone. Only after the activity-dependent depletion or 
time-dependent depriming of these SVs (20, 40) would the requirement for NSF 
to prime SVs become evident. It therefore appears that NSF disassembles 
cis-SNARE complexes over a time scale of a few seconds under physiological 
conditions. Sorting of disassembled v- and t-SNARE proteins to their appropriate 
compartments would then occur by the binding to compartment-specific 
partners during or shortly after fusion (Fig. S2, arrow). Such a mechanism 
permits sorting of SNAREs while the membrane domains of SVs and the plasma 
membrane retain their identity. It can also account for experimental 
observations that SNARE complexes containing both v- and t-SNAREs exist in 
vesicle membranes (41-47) and that v-SNAREs can remain on the plasma 
membrane after endocytosis (48). 
 
At first glance, this model could be challenged by biochemical measurements 
suggesting that both SVs and the plasma membrane contain an excess of free 
SNARE proteins (47, 49, 50), making the pre-fusion production of free SNARE 
proteins for trans-SNARE complex formation unnecessary. However, 
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biochemical studies consider mainly bulk compartments such as reserve pool 
vesicles or total plasma membrane, precluding extrapolation to the subset of 
SNARE proteins directly involved in exocytosis. Further, the presence of even a 
small number of cis-SNARE complexes at the fusion site might serve as a steric 
hindrance to membrane fusion, despite the presence of free SNARE proteins. 
 
In addition to cis-SNARE complexes, NSF could act upon several other protein 
complexes. For example, αSNAP recruitment to a complex containing only 
syntaxin and SNAP-25 (51, 52) causes strong stimulation of NSF ATPase activity 
and complex disassembly (53). Tomosyn/t-SNARE complexes also can be 
disassembled by αSNAP-stimulation of NSF (54). These mechanisms could 
regulate the availability of a pool of plasma membrane t-SNARES for the 
formation of trans-SNARE complexes. NSF has been suggested to regulate the 
trapping of t-SNAREs into hotspots by dynamin (55). The ATPase activity of NSF 
could release t-SNARES from this trap just prior to trans-SNARE pairing and 
membrane fusion (55). In summary, photolysis of cNSF3 could cause abrupt 
freezing of cis-SNARE complexes, binary SNARE complexes, tomosyn-t-SNARE 
complexes  and/or t-SNARE/dynamin complexes. Such effects, either separately 
or in concert, could account for the slower, activity-dependent component of the 
response to uncaged NSF3. Together, these mechanisms may constitute the 
contributions of NSF to ATP-dependent priming (42) of SVs.  
 
The fast NSF-dependent reaction that affects release kinetics (steps 3-4 in Fig. 7) 
could result from a desynchronization of release events or a direct modulation of 
the fusion reaction by NSF, as has been suggested in other studies (56-58). The 
fast NSF3 effect is similar in time course to priming of the fusion machinery, 
which precedes release by 45-250 ms (59) and requires ATP hydrolysis (14, 60, 
61). Although the rate of αSNAP-stimulated ATPase activity in the native 
environment of the nerve terminal is unknown,  the ATPase activity of NSF in 
vitro (62) appears to be too slow to support a reaction that occurs within a time 
scale of 0.2 seconds. The fast effect could be related to an ATPase-independent 
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function of NSF (56), perhaps aiding proper folding and zippering up of SNARE 
complexes or optimizing the state of oligomerization of SNAREs (63).  
 
In conclusion, or work indicates that NSF function is critical for highly dynamic 
reactions that occur immediately before synaptic vesicles fuse with the 
presynaptic plasma membrane to release neurotransmitter. In addition to 
answering a long-standing question about the timing of NSF action during 
synaptic vesicle trafficking, our results indicate a new potential locus for rapid 
regulation of neurotransmitter release by signals such as nitric oxide (28) or 
protein kinases (64-66). Our work also is the first to define the precise timing of 
any protein-protein interaction involved in synaptic vesicle exocytosis, hence 
providing a temporal benchmark for future studies of the timing of other 
exocytotic interactions. 
 
 
 
Materials and Methods 
 
Caged peptides 
5-(carboxymethoxy)-2-nitrobenzyloxycarbonyl (CMNCBZ) caged lysine (67, 68) 
was synthesized as described in Supplementary Information. This peptide was 
used to synthesize the following peptides: Caged NSF3, 
TGKTLIAR[K]IGKMLNATEPK (squid sequence), caged scrambled NSF3 =  
GNIELATKT[K]ARIKLTMPKG. Details of peptide synthesis are provided in 
Supplementary Information. 
 
Electrophysiology 
The stellate ganglion was dissected from Loligo pealei  and  recordings of 
synaptic transmission were done as described previously (69, 70). Caged 
peptide was microinjected into the giant presynaptic terminal and a shuttered 
argon ion laser (Coherent Inc., Santa Clara, CA) was used for peptide photolysis. 
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More details are described in Supplementary Information.  
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Figure Legends 
Figure 1: Pre or post fusion function of NSF  
A. Model depicting NSF acting upstream of neurotransmitter release. NSF 
(yellow), αSNAP (green), v-SNARE (blue), t-SNAREs (orange). 
B. Model showing a post-fusion role of NSF. 
C. Because the synaptic vesicle (SV) cycle requires 45-90 seconds (left), a 
pre-fusion block of NSF action would occur much more quickly (center), while a 
post-fusion block would require all or most of the 45-90 seconds (right).  
 
Figure 2: Design of the caged NSF3 peptide (cNSF3) 
A. Sequence of the squid NSF3 peptide. Underlined residue is G309, the 
Comatose locus (corresponds to G274 in NSF-1 of Drosophila) and the caged 
lysine residue K307 is in red and is marked with an asterisk. 
B. Schematic representation of NSF with structural elements contributing to the 
lateral surfaces of the N and D1 domains. Upper - N, D1 and D2 denote the 
three domains of a NSF monomer, the schematic side-view shows only three 
subunits of the hexamer. Lower – Predicted structure of the N and D1 domains 
of NSF, based on coordinates taken from the NSF homologue P97(71). The 2.5 
nm thick slab shows: N-domain in orange, D1-domain in yellow, the NSF3 
peptide in blue, and the caged lysine residue in red. Other active NSF peptides 
(30) are indicated in green (NSF1) and purple (NSF2). 
C. Photochemistry of CMNCBZ-caged lysine. Absorption of a photon of UV light 
rapidly removes most of the cage, while a slower spontaneous decarboxylation 
removes the rest and generates free CO2 (34). 
 
Figure 3: Photolysis of cNSF in the presynaptic terminal 
A. Inhibition of synaptic transmission after uncaging microinjected cNSF3 (0.75 
mM) in the giant terminal of the squid. Action potentials were elicited every 1 s. 
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Simultaneous presynaptic (Vpre) and postsynaptic (Vpost) voltage recordings 
immediately before (black) and after (red) uncaging (stimulation artefact 
blanked).  
B. Rapid time course of inhibitory effects of uncaged NSF3. The slope of the PSP 
was determined from fits to the initial rise of the PSP and plotted as a function of 
time. UV light was applied for 50 ms (arrow, ~ 150 mJ/mm2). Terminal injected 
with 0.75 mM cNSF3. 
C. Concentration-dependent inhibition of synaptic transmission by caged NSF3 
peptide (black closed circles, n=14) and uncaged peptide (red open circles, 
n=14). See Supplementary Methods for further details. 
D. Lack of effect of photolysis of caged scrambled NSF3 peptide (0.64 mM). UV 
light (750 mJ/mm2) was applied three times at the point indicated by the arrow. 
 
Figure 4: Differential onset of amplitude and kinetic effect 
A. Simultaneous pre - and postsynaptic recordings before (black line) and after 
(red line) photolysis of caged NSF3 peptide. Synapse was stimulated at 1 Hz.  
B. Scaled PSCs, from the experiment shown in A, before (black) and after (red) 
uncaging of NSF3. 
C. Onset of changes in PSC amplitude (top), PSC rise time (20-80%; center) 
and PSC decay time constant (lower). UV light (150 mJ/mm2) was applied at the 
10 s time point (gray bar). 
 
Figure 5: Activity-dependency and onset of fast effect  
A. Time course of the slow effect of uncaged NSF3 on PSC amplitude. The 
fractional reduction of PSC amplitude is plotted as a function of time after 
peptide photolysis. Continuous curves are exponential functions with time 
constants of 1.6 s (5 Hz) and 3.1 s (0.2 Hz). Data points reflect 7 and 10 
independent experiments, respectively. 
B. Time course of the rapid effect of uncaged NSF3 on PSC kinetics. The 
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fractional slowing of PSC decay time constant is plotted as a function of the time 
interval (Δt) between the UV light flash (UV) and the presynaptic stimulus 
(APpre). The experimental protocol is illustrated in the inset. Data from 8 
independent experiments using two stimulus frequencies (0.2 Hz; circles and 1 
Hz; triangles) were pooled (squares) because the two data sets did not differ. 
The continuous curve is an exponential function with a time constant of 0.22 s.  
C. Time course of the rapid inhibition of PSC kinetics by uncaged NSF3 under 
conditions of minimal synaptic activity (0.03 Hz). The continuous curve is an 
exponential function with a time constant of 0.5 s. Each point is from 2-5 
experiments.  
D. Concentration-dependent inhibition of PSC amplitude (open circles, IC50 = 
0.28 ± 0.02 mM) and decay kinetics (closed circles, IC50 = 0.06 ± 0.01 mM) by 
uncaged NSF3). Each point is from 3-9 experiments.  
 
 
Figure 6: Endocytosis unaffected by cNSF photolysis   
Time course of endocytosis before (grey) and after (red) photolysis of cNSF3. 
Relative Cm change shown as a range (mean ± SEM, grey zone and space 
between red lines) Five independent experiments. High frequency stimulation 
(grey bar), photolysis immediately thereafter. 
 
Figure 7: Model of NSF function and life-cycle of SNARE proteins 
Model for the dual actions of NSF in transmitter release. A complete cycle of SV 
trafficking requires 45-90 seconds (27). After vesicle docking (1-2 transition), 
the slow action of NSF primes synaptic vesicles over a time scale of seconds. 
Readily releasable vesicles (3; highlighted red) can then fuse in a 
calcium-dependent reaction that is influenced by NSF acting within a time 
window of less than 0.5 seconds. Following membrane fusion, vesicles bud off 
from the plasma membrane (5-6 transition) and are then recycled (6-1 
transition). 
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Supplementary Information 
 
 
Materials and Methods 
 
Chemical synthesis of caged lysine.  
The 5-(carboxymethoxy)-2-nitrobenzyloxycarbonyl (CMNCBZ) caging group 
has been used successfully to cage the amino groups of fluorescent probes (1, 
2). UV photolysis rapidly liberates a carbamic acid, which spontaneously 
decarboxylates to give the free amine. In the current experiments, the anionic 
carboxylate of the caging group functions to disguise the normal positive 
charge of the lysine residue side chain amino group to which it is attached, 
thus reducing the likelihood of it being recognized by the binding partner of 
NSF3. Before peptide synthesis, the caging group carboxylate was protected as 
an acid labile t-butyl ester. This strategy allows for normal FMOC-based solid 
phase peptide synthesis after incorporation of the caged lysine residue, but the 
caging group t-butyl ester is cleaved to a carboxylate upon acid-mediated 
cleavage of the final peptide from the synthesis resin.  
e-(t-Bu-CMNCBZ)-a-FMOC-(L)-lysine. a-FMOC-(L)-lysine (5.88 g, 16 mmol) is 
added to a solution of the chloroformate of 5-(t-butoxycarbonylmethoxy)-2-
nitrobenzyl alcohol (16 mmol) in 60 ml anhydrous dichloromethane, followed 
by diisopropylethylamine (32 mmol). The resulting mixture is stirred for 6h, 
then concentrated in vacuo. The residue is purified by flash chromatography 
using chloroform/methanol/acetic acid as eluant to afford e-(t-Bu-CMNCBZ)-a-
FMOC-(L)-lysine as 3.88 g (36%) of a pale brown powder: 1H NMR (CD2Cl2) d 
8.15 (d, 1H), 7.71 (d, 2H), 7.61 (m, 2H), 7.40 (t, 2H), 7.29 (t, 2H), 7.08 (t, 
1H), 5.33 (s, 2H), 4.82 (s, 2H), 4.34 (d, 2H), 4.23 (t, 1H), 3.17 (br d, 3H), 1.9 
(m, 2H), 1.77 (m, 2H), 1.53 (m, 2H), 1.44 (s, 9H); m/z 678 (677 calculated 
for C35H39N3O11). 
 
Caged peptides 
The following peptides were synthesized: Caged NSF3, 
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TGKTLIAR[K]IGKMLNATEPK (squid sequence), caged scrambled NSF3 =  
GNIELATKT[K]ARIKLTMPKG. Peptides were synthesized on an Advanced 
Chemtech 396 MBS synthesizer using standard FMOC chemistry. All procedures 
were performed under reduced light conditions to prevent photolysis of the 
caged amino acids. FMOC-Rink amide MBHA resin was used to yield an amide 
at the carboxy terminus. The caged amino acids were synthesized as described 
above and non-caged amino acids were from Anaspec (San Jose, Ca). NMP was 
used for swelling the resin, Pip for deprotection and the amino acids were 
incorporated using HOBt/HBTU/DIEA activation, two couplings each. The caged 
amino acids were coupled only once overnight. The well plate was removed 
from the synthesizer, reagents added, covered in aluminum foil and placed 
onto the shaker (Ocelot). The next day the plate was put back onto the 
synthesizer, the fluids drained, and synthesis continued as normal. Most 
peptides were acetylated by the same coupling methods as above using 30% 
acetic anhydride in DMF. The peptides were cleaved while mixing in 94.5% 
TFA, 2.5% Water, 2% EDT, and 1% TIS at room temperature for 2 hours. The 
peptides were then precipitated with ethyl ether, placed at -80°C for 2 hours, 
centrifuged for 30 minutes at 2000 rpm, decanted, and the pellet resuspended 
in sufficient formic acid to dissolve the pellet, followed by addition of 0.1% 
TFA/Water to equilibrate for application to HPLC.  The peptides were purified 
on a Gilson HPLC using C18 reverse phase (Phenomenex column, 250 x 
21.20mm, 10 micron, 300 Å); buffer A, 0.1% TFA/Water; buffer B, 0.1% TFA 
in acetonitrile. The fractions containing the correct peptide according to mass 
calculation were identified using MALDI (Perseptive Biosystems Voyager DE), 
then frozen, lyophilized, and stored at –22° C wrapped in aluminum foil. 
 
Electrophysiology 
The stellate ganglion was dissected from Loligo pealei supplied by the Marine 
Resources Center of the Marine Biological Laboratory. Simultaneous pre- and 
postsynaptic intracellular recordings from the giant synapse were carried out 
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with sharp electrodes positioned in the terminal and postsynaptic axon (3). 
Action potentials were stimulated with a third electrode in the presynaptic axon 
every 0.2 to 30s. The slope of the postsynaptic potential (PSP) in current-
clamp recordings was taken as a measure of neurotransmitter release. To 
determine changes in the kinetics of release, the postsynaptic axon was 
voltage-clamped with a 2-microelectrode voltage clamp (Axoclamp-2A; Axon 
Instruments). Postsynaptic currents were filtered at 5 kHz and digitized at 33 
kHz. The stellate ganglion was superfused at 14-15˚C with squid saline 
containing (in mM): 466 NaCl, 54 MgCl2, 11 CaCl2, 10 KCl, 3 NaHCO3, and 10 
HEPES, pH 7.2. Recording pipettes were filled with 3 M KCl or 7 M CsCl. Signals 
were digitized with a TL1 board and recorded with a custom-made software 
written in Axobasic by F. Schweizer (UCLA). Off-line analysis of kinetic 
parameters was done with an automized procedure written in Igor 
(WaveMetrics, Lake Oswego, OR). All numbers are given as mean ± SEM 
unless noted otherwise.  
 
Peptide injection and photolysis 
Lyophyllized peptide was dissolved in deionized water in the presence of 10% 
dimethylsulfoxide (DMSO) to facilitate solubility. The concentration of the 
peptide solution was 10 to 20 mM as determined spectrophotometrically (lmax, 
CMNCBZ = 305 nm, e = 9200 M-1cm-1). Rhodamine dextran (10 µM, 10 kDa 
dextran, Molecular Probes) was added to the solution to monitor loading of the 
terminal and estimation of the free peptide concentration in the terminal. The 
injection solution was supplemented with 10 mM KCl to facilitate voltage 
recordings. Test injections of a 10% DMSO solution containing Rhodamine 
dextran did not affect neurotransmitter release (5 ± 7 % change in slope, 
n=4), presumably because DMSO diffused away as it was injected. Only 
terminals with damage-free recordings, as judged from lack of changes in 
neurotransmitter release following microelectrode impalements, were used. 
When testing caged scrambled NSF3 peptide, successful illumination was 
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confirmed by photolysing caged fluorescein dextran that was coinjected into 
the terminal (3 µM). 
A constant wave argon ion laser (Coherent Inc., Santa Clara, CA) was used to 
generate UV light in the range of 342 to 354 nm with a total output power of 
about 2 W. The laser beam was directed into the specimen from below the 
microscope stage by using highly reflective mirrors (Newport Corporation, 
Irvine, CA). A uniform beam profile of about 1.2 mm diameter was produced in 
the focal plane of the specimen; this light spot covers the entire presynaptic 
terminal. A mechanical shutter (Vincent Associates, Rochester, NY) was used 
to control the amount of laser light (20 to 100 mJ). 50 mJ of UV light 
photolyzed ~40% of the cage, as determined with caged fluorescent dyes.  
The dose-response curves shown in Fig. 3C were determined as follows. The 
curve for cNSF3, reflecting the residual activity of the caged NSF3 peptide, was 
established from the extent of inhibition caused by different concentrations of 
cNSF3 injected into the terminal. To generate the curve for uncaged NSF3 
peptide, we first calculated its concentration by multiplying the cNSF3 
concentration with the known uncaging efficiency. The observed degree of 
inhibition after photolysis reflected the combined presence of uncaged NSF3 
and remaining cNSF3. The inhibition produced by uncaged NSF3 alone was 
derived by extrapolating the inhibitory effect of the remaining cNSF3 
concentration from the cNSF3 curve and subtracting this value from the total 
inhibition.  
 
Capacitance recordings 
For presynaptic capacitance measurement, two microelectrodes were inserted 
into the presynaptic terminal to control presynaptic membrane potential under 
voltage clamp, similar as previously described(4). Membrane capacitance (Cm) 
was monitored in the two-electrode voltage-clamp configuration similar as 
previously reported(5). Briefly, Cm was determined from the current response 
to a triangular, symmetrical voltage command repetitively applied at up to 60 
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Hz. The hyper and depolarizing ramps (±25 mV in 4~10 ms) elicited 
membrane currents that were the sum of resistive and capacitive components. 
The capacitive current was determined by subtracting the down-ramp current 
integral from the up-ramp current integral. Then, dividing the capacitive 
current by the stimulus voltage yielded Cm.  
 
Supplementary Discussion 
Specificity of NSF3 peptides  
The specificity of NSF peptides has been demonstrated by several studies using 
different paradigms (references 28-31). The arguments that the NSF peptides 
exert their effects specifically by interfering with NSF are as follows: 
  
1) Two peptides derived from the D1 domain of NSF (NSF2 and NSF3) exert 
similar effect on the amplitude and kinetics of synaptic transmission, while 
three other peptides derived from the same domain do not show any effect at 
all. The segments of the domain from which the peptides were derived are 
spatially clustered at a location close to the ATP binding site, whereas the 
ineffective peptides were derived from regions which are exposed to the inside 
of the NSF multimer (Kuner, T., Tokumaru, H. & Augustine, G. J. (2002) in 
Peptide-lipid interactions, eds. Simon, S. A. & McIntosh, T. J. (Academic Press, 
San Diego), Vol. 52, pp. 552-570.). This seems to be very strong evidence for 
the specificity of peptide action, because there is very little chance that two 
peptides with completely different primary sequences would exert the same 
physiological effects.  
 
2. It has been demonstrated that NSF2 and NSF3 peptides selectively interfere 
with ATPase function in a biochemical assay containing only aSNAP and NSF 
proteins (refs. 29, 30). The inhibition of ATPase function occurred at peptide 
concentrations similar to those used in the nerve terminal (ref. 30). It also has 
been demonstrated that the NSF2 peptide interferes with the NSF-dependent 
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disassembly of the SNARE complex (ref. 28).  
 
3. A single point mutation of the NSF3 peptide, resembling the Drosophila 
comatose mutation, completely prevents the peptide from inhibiting either 
ATPase activity or synaptic transmission (ref. 30).  
 
 
Supplementary Figure 
   
Figure S1:  
Postulated dynamics of SNARE proteins during exocytosis. SV in the reserve 
pool contains cis-SNARE complexes (6). (A) αSNAP and NSF bind to cis-SNARE 
complexes on SV and plasma membranes (latter not shown for clarity). (B)  
αSNAP and SNAREs stimulate the ATPase activity of NSF, causing  disassembly 
of cis-SNARE complexes. NSF may remain bound on SV even after unbinding of 
αSNAP (7). (C) Free SNARE proteins form trans-SNARE complexes. (D) During 
or shortly after membrane fusion, when SV and plasma membranes are 
continuous, SNARE proteins are sorted onto the correct compartment. Acceptor 
proteins for respective SNARE proteins are not shown for clarity. (E) Cis-
SNARE complexes are retrieved along with the SV membrane during 
endocytosis. (F) Recycling SVs contain cis-SNARE complexes (8). 
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